The Drug Information System (DIS) enables to monitor: incidence (the numbers of newly registered problem drug users); prevalence (the numbers of existing problem users visiting treatment/contact centres in a certain time period or as of a certain date); types of used drugs, manner of their application, frequency of use, their availability, purity; health (but also social consequences) of drug use (hepatitis, HIV; social and economic consequences); demographic profile of affected persons (age, sex, employment, education, etc.); time trends showing potential changes of the above specified indicators, including changes in the geographic distribution. Hygienic Service was mandated to create and operate the DIS in the Czech Republic. The system has been in operation since 1 January 1995 and it is based on the monitoring of basic health indicators.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study.
BMC Pharmacol Toxicol
January 2025
Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China.
Purpose: This study aims to assess the risks associated with drug-induced macular edema and to examine the epidemiological characteristics of this condition.
Methods: This study analyzed data from the U.S.
Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study.
J Pharm Health Care Sci
January 2025
Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose, 204-8588, Japan.
Background: The Anticholinergic Risk Scale and Total Anticholinergic Load were developed to assess the risks associated with anticholinergic drugs. Recently, the Japan Anticholinergic Risk Scale was introduced; however, the total anticholinergic load for adverse events has not been clarified, and the criteria for risk assessment in clinical practice have not been established. In this study, we used data from the Japanese Adverse Drug Event Report (JADER) database provided by the Pharmaceuticals and Medical Devices Agency to determine the total anticholinergic load associated with reported adverse events related to anticholinergic syndrome.
View Article and Find Full Text PDFIntricate interplay of CRISPR-Cas systems, anti-CRISPR proteins, and antimicrobial resistance genes in a globally successful multi-drug resistant Klebsiella pneumoniae clone.
Genome Med
January 2025
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Background: Klebsiella pneumoniae is one of the most prevalent pathogens responsible for multiple infections in healthcare settings and the community. K. pneumoniae CG147, primarily including ST147 (the founder ST), ST273, and ST392, is one of the most globally successful MDR clone linked to various carbapenemases.
View Article and Find Full Text PDFPoor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model.
Ann Clin Microbiol Antimicrob
January 2025
Laboratoire des Mycobactéries, Institut des Agents Infectieux, Laboratoire de Biologie Médicale Multi-Site, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
Background: Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is uncertain. Inducible resistance to macrolides (macrolides-iR) has been associated with poor clinical response in pulmonary infections, whilst for extra-pulmonary infections data are scarce.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!